A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
| dc.contributor.author | Starling, N | |
| dc.contributor.author | Vázquez-Mazón, F | |
| dc.contributor.author | Cunningham, D | |
| dc.contributor.author | Chau, I | |
| dc.contributor.author | Tabernero, J | |
| dc.contributor.author | Ramos, F | |
| dc.contributor.author | Iveson, T | |
| dc.contributor.author | Saunders, Mark P | |
| dc.contributor.author | Aranda, E | |
| dc.contributor.author | Countouriotis, A | |
| dc.contributor.author | Ruiz-Garcia, A | |
| dc.contributor.author | Wei, G | |
| dc.contributor.author | Tursi, J | |
| dc.contributor.author | Guillen-Ponce, C | |
| dc.contributor.author | Carrato, A | |
| dc.date.accessioned | 2012-05-01T11:41:56Z | |
| dc.date.available | 2012-05-01T11:41:56Z | |
| dc.date.issued | 2012-01 | |
| dc.identifier.citation | A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. 2012, 23 (1):119-27 Ann Oncol | en_GB |
| dc.identifier.issn | 1569-8041 | |
| dc.identifier.pmid | 21447616 | |
| dc.identifier.doi | 10.1093/annonc/mdr046 | |
| dc.identifier.uri | http://hdl.handle.net/10541/221357 | |
| dc.description.abstract | This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i.v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC). | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMO | en_GB |
| dc.title | A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Medicine, Royal Marsden Hospital, NHS Foundation Trust, London and Sutton, UK. | en_GB |
| dc.identifier.journal | Annals of Oncology | en_GB |
| html.description.abstract | This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i.v. and l-leucovorin 200 mg/m2 given over 120 min on day 1, followed by 5-FU 400 mg/m2 bolus and then 2400 mg/m2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC). |